RELX (REL) Investor Presentation summary

Business overview and strategy

• Operates as a global provider of information-based analytics and decision tools, serving professional and business customers in over 180 countries.

• Focuses on organic growth, supported by targeted acquisitions, with a primary aim to deliver enhanced value through advanced analytics and decision tools.

• Employs over 36,000 people worldwide and is listed in London, Amsterdam, and New York.

• Maintains a strong market position across four segments: Risk, Scientific, Technical & Medical (STM), Legal, and Exhibitions.

• Purpose-driven, aiming to benefit society by supporting research, healthcare, legal justice, fraud prevention, and market access.

Financial performance and growth

• 2024 revenue reached £9.4bn, with adjusted operating profit of £3.2bn and EBITDA margin of 39.5%.

• H1 2025 saw underlying revenue growth of 7%, adjusted operating profit growth of 9%, and adjusted EPS growth of 10%.

• Cash flow conversion remains high at 97%, with net debt/EBITDA at 1.8x and market capitalization of £64bn as of October 2025.

• Dividend per share has grown consistently, with a 7% increase in the latest period.

• Return on invested capital and adjusted cash flow conversion have remained strong, supporting ongoing investment and shareholder returns.

Segment highlights

• Risk: Delivered H1 2025 revenue of £1,748m, with 9% underlying revenue growth, driven by analytics for fraud prevention, insurance, and compliance.

• STM: H1 2025 revenue of £1,323m, with 5% underlying revenue growth, leading in scientific publishing and analytics platforms.

• Legal: H1 2025 revenue of £900m, with 9% underlying revenue growth, expanding use of analytics, decision tools, and generative AI in legal workflows.

• Exhibitions: H1 2025 revenue of £581m, with 8% underlying revenue growth, strong recovery and ongoing digital transformation.